Characterisation of the Mopra Radio Telescope at 16--50 GHz

We present the results of a programme of scanning and mapping observations of astronomical masers and Jupiter designed to characterise the performance of the Mopra Radio Telescope at frequencies between 16-50 GHz using the 12-mm and 7-mm receivers. We use these observations to determine the telescope beam size, beam shape and overall telescope beam efficiency as a function of frequency. We find that the beam size is well fit by $\lambda$/$D$ over the frequency range with a correlation coefficient of ~90%. We determine the telescope main beam efficiencies are between ~48-64% for the 12-mm receiver and reasonably flat at ~50% for the 7-mm receiver. Beam maps of strong H$_2$O (22 GHz) and SiO masers (43 GHz) provide a means to examine the radial beam pattern of the telescope. At both frequencies the radial beam pattern reveals the presence of three components, a central `core', which is well fit by a Gaussian and constitutes the telescopes main beam, and inner and outer error beams. At both frequencies the inner and outer error beams extend out to approximately 2 and 3.4 times the full-width half maximum of the main beam respectively. Sources with angular sizes a factor of two or more larger than the telescope main beam will couple to the main and error beams, and therefore the power contributed by the error beams needs to be considered. From measurements of the radial beam power pattern we estimate the amount of power contained in the inner and outer error beams is of order one-fifth at 22 GHz rising slightly to one-third at 43 GHz.Comment: Accepted for publication in PAS

Measuring Metacognition in Cancer: Validation of the Metacognitions Questionnaire 30 (MCQ-30)

Objective The Metacognitions Questionnaire 30 assesses metacognitive beliefs and processes which are central to the metacognitive model of emotional disorder. As recent studies have begun to explore the utility of this model for understanding emotional distress after cancer diagnosis, it is important also to assess the validity of the Metacognitions Questionnaire 30 for use in cancer populations. Methods 229 patients with primary breast or prostate cancer completed the Metacognitions Questionnaire 30 and the Hospital Anxiety and Depression Scale pre-treatment and again 12 months later. The structure and validity of the Metacognitions Questionnaire 30 were assessed using factor analyses and structural equation modelling. Results Confirmatory and exploratory factor analyses provided evidence supporting the validity of the previously published 5-factor structure of the Metacognitions Questionnaire 30. Specifically, both pre-treatment and 12 months later, this solution provided the best fit to the data and all items loaded on their expected factors. Structural equation modelling indicated that two dimensions of metacognition (positive and negative beliefs about worry) were significantly associated with anxiety and depression as predicted, providing further evidence of validity. Conclusions These findings provide initial evidence that the Metacognitions Questionnaire 30 is a valid measure for use in cancer populations

Physical Properties of Giant Molecular Clouds in the Large Magellanic Cloud

The Magellanic Mopra Assessment (MAGMA) is a high angular resolution CO mapping survey of giant molecular clouds (GMCs) in the Large and Small Magellanic Clouds using the Mopra Telescope. Here we report on the basic physical properties of 125 GMCs in the LMC that have been surveyed to date. The observed clouds exhibit scaling relations that are similar to those determined for Galactic GMCs, although LMC clouds have narrower linewidths and lower CO luminosities than Galactic clouds of a similar size. The average mass surface density of the LMC clouds is 50 Msol/pc2, approximately half that of GMCs in the inner Milky Way. We compare the properties of GMCs with and without signs of massive star formation, finding that non-star-forming GMCs have lower peak CO brightness than star-forming GMCs. We compare the properties of GMCs with estimates for local interstellar conditions: specifically, we investigate the HI column density, radiation field, stellar mass surface density and the external pressure. Very few cloud properties demonstrate a clear dependence on the environment; the exceptions are significant positive correlations between i) the HI column density and the GMC velocity dispersion, ii) the stellar mass surface density and the average peak CO brightness, and iii) the stellar mass surface density and the CO surface brightness. The molecular mass surface density of GMCs without signs of massive star formation shows no dependence on the local radiation field, which is inconsistent with the photoionization-regulated star formation theory proposed by McKee (1989). We find some evidence that the mass surface density of the MAGMA clouds increases with the interstellar pressure, as proposed by Elmegreen (1989), but the detailed predictions of this model are not fulfilled once estimates for the local radiation field, metallicity and GMC envelope mass are taken into account.Comment: 28 pages, 10 figures, accepted by MNRA

Kish excavations, 1923-1933: with a microfiche catalogue of the objects in Oxford excavated by the Oxford-Field Museum, Chicago, Expedition to Kish in Iraq, 1923-1933

https://commons.library.stonybrook.edu/amar/1329/thumbnail.jp

Cemeteries of the first millennium B.C. at Deve Hüyük, near Carchemish, salvaged by T.E. Lawrence and C.L. Woolley in 1913

https://commons.library.stonybrook.edu/amar/1522/thumbnail.jp

Supporting carers to manage pain medication in cancer patients at the end of life: A feasibility trial

Background: Carers of people with advanced cancer play a significant role in managing pain medication, yet they report insufficient information and support to do so confidently and competently. There is limited research evidence on the best ways for clinicians to help carers with medication management. Aims: To develop a pain medicines management intervention (Cancer Carers Medicines Management) for cancer patients’ carers near the end of life and evaluate feasibility and acceptability to nurses and carers. To test the feasibility of trial research procedures and to inform decisions concerning a full-scale randomised controlled trial. Design: Phase I-II clinical trial. A systematic, evidence-informed participatory method was used to develop CCMM: a nurse-delivered structured conversational process. A two-arm, cluster randomised controlled feasibility trial of Cancer Carers Medicines Management was conducted, with an embedded qualitative study to evaluate participants’ experiences of Cancer Carers Medicines Management and trial procedures. Setting: Community settings in two study sites. Participants: Phase I comprises 57 carers, patients and healthcare professionals and Phase II comprises 12 nurses and 15 carers. Results: A novel intervention was developed. Nurses were recruited and randomised. Carer recruitment to the trial was problematic with fewer than predicted eligible participants, and nurses judged a high proportion unsuitable to recruit into the study. Attrition rates following recruitment were typical for the study population. Cancer Carers Medicines Management was acceptable to carers and nurses who took part, and some benefits were identified. Conclusion: Cancer Carers Medicines Management is a robustly developed medicines management intervention which merits further research to test its effectiveness to improve carers’ management of pain medicines with patients at the end of life. The study highlighted aspects of trial design that need to be considered in future research

Effectiveness of cognitive-behavioural therapy for depression in advanced cancer: CanTalk randomised controlled trial

BACKGROUND: Depression is one of the most common mental disorders in people with advanced cancer. Although cognitive-behavioural therapy (CBT) has been shown to be effective for depression in people with cancer, it is unclear whether this is the case for people with advanced cancer and depression. // AIMS: We sought to determine whether CBT is more clinically effective than treatment as usual (TAU) for treating depression in people with advanced cancer (trial registration number ISRCTN07622709). // METHOD: A multi-centre, parallel-group single-blind randomised controlled trial comparing TAU with CBT (plus TAU). Participants (n = 230) with advanced cancer and depression were randomly allocated to (a) up to 12 sessions of individual CBT or (b) TAU. The primary outcome measure was the Beck Depression Inventory-II (BDI-II). Secondary outcome measures included the Patient Health Questionnaire-9, the Eastern Cooperative Oncology Group Performance Status, and Satisfaction with Care. // RESULTS: Multilevel modelling, including complier-average intention-to-treat analysis, found no benefit of CBT. CBT delivery was proficient, but there was no treatment effect (-0.84, 95% CI -2.76 to 1.08) or effects for secondary measures. Exploratory subgroup analysis suggested an effect of CBT on the BDI-II in those widowed, divorced or separated (-7.21, 95% CI -11.15 to -3.28). // CONCLUSIONS: UK National Institute for Health and Care Excellence (NICE) guidelines recommend CBT for treating depression. Delivery of CBT through the Improving Access to Psychological Therapies (IAPT) programme has been advocated for long-term conditions such as cancer. Although it is feasible to deliver CBT through IAPT proficiently to people with advanced cancer, this is not clinically effective. CBT for people widowed, divorced or separated needs further exploration. Alternate models of CBT delivery may yield different results. // DECLARATION OF INTEREST: M.S. is a member of the Health Technology Assessment General Board

Effectiveness of cognitive-behavioural therapy for depression in advanced cancer: CanTalk randomised controlled trial

BACKGROUND: Depression is one of the most common mental disorders in people with advanced cancer. Although cognitive-behavioural therapy (CBT) has been shown to be effective for depression in people with cancer, it is unclear whether this is the case for people with advanced cancer and depression. // AIMS: We sought to determine whether CBT is more clinically effective than treatment as usual (TAU) for treating depression in people with advanced cancer (trial registration number ISRCTN07622709). // METHOD: A multi-centre, parallel-group single-blind randomised controlled trial comparing TAU with CBT (plus TAU). Participants (n = 230) with advanced cancer and depression were randomly allocated to (a) up to 12 sessions of individual CBT or (b) TAU. The primary outcome measure was the Beck Depression Inventory-II (BDI-II). Secondary outcome measures included the Patient Health Questionnaire-9, the Eastern Cooperative Oncology Group Performance Status, and Satisfaction with Care. // RESULTS: Multilevel modelling, including complier-average intention-to-treat analysis, found no benefit of CBT. CBT delivery was proficient, but there was no treatment effect (-0.84, 95% CI -2.76 to 1.08) or effects for secondary measures. Exploratory subgroup analysis suggested an effect of CBT on the BDI-II in those widowed, divorced or separated (-7.21, 95% CI -11.15 to -3.28). // CONCLUSIONS: UK National Institute for Health and Care Excellence (NICE) guidelines recommend CBT for treating depression. Delivery of CBT through the Improving Access to Psychological Therapies (IAPT) programme has been advocated for long-term conditions such as cancer. Although it is feasible to deliver CBT through IAPT proficiently to people with advanced cancer, this is not clinically effective. CBT for people widowed, divorced or separated needs further exploration. Alternate models of CBT delivery may yield different results. // DECLARATION OF INTEREST: M.S. is a member of the Health Technology Assessment General Board